Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ArthroCare launches ArthroWand temperature monitors

This article was originally published in Clinica

Executive Summary

Minimally-invasive surgery specialist ArthroCare has launched its Ambient ArthroWand line, designed to monitor the temperature of circulating fluid during arthroscopic surgery. These procedures treat the inside of a joint, such as the knee or shoulder, using a device inserted through a small incision. ArthroCare's new products, including the Ambient Super MultiVac 50, the Ambient Super TurboVac 90, and the Ambient CoVac 50 and 70, use radiofrequency to measure the temperature of irrigation fluid in these joints in real time. This fluid is used to distend the joint and make a surgical space. The Austin, Texas firm's Quantum 2 device then provides visual feedback. The information allows surgeons to carry out procedures within the correct temperature range.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel